Payment overview · 2025
General Payments
$992.45
63 reported records · 16 companies
Healthcare provider profile · identity verified
Ahab Gabriel
Allopathic & Osteopathic Physicians|Internal Medicine · EAST BRUNSWICK, NJ · NPI 1285729319
Verified facts
What the public records show
CMS Open Payments records show Ahab Gabriel received $992.45 in general payments during 2025 across 63 reported records.
Novo Nordisk Inc accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $198.26 | 20.0% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $181.83 | 18.3% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $100.72 | 10.2% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $91.26 | 9.2% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.74 | 8.4% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $52.48 | 5.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.08 | 3.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.43 | 3.7% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $35.86 | 3.6% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $33.71 | 3.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.94 | 3.3% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.04 | 3.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.52 | 2.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.59 | 1.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $17.31 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.68 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $962.58 | 61 |
| Education | $29.87 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $181.83 | 14 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $181.83 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.38 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $123.38 | 7 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $91.26 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $68.12 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $52.48 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $50.80 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.92 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.92 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.24 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.08 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.43 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $35.86 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $33.71 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.94 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $32.04 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.52 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 50 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 212 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 122 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 191 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 198 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 276 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
50 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
191 | 47 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
212 | 56 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
37 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
80 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
187 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
198 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
118 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
276 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
122 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 389 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 385 | 115 |
| Omeprazole | Omeprazole | 375 | 103 |
| Diclofenac Sodium | Diclofenac Sodium | 360 | 102 |
| Gabapentin | Gabapentin | 331 | 89 |
| Losartan Potassium | Losartan Potassium | 281 | 68 |
| Ozempic | Semaglutide | 276 | 43 |
| Metformin Hcl | Metformin Hcl | 253 | 67 |
| Metformin Hcl Er | Metformin Hcl | 242 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 228 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 214 | 50 |
| Farxiga | Dapagliflozin Propanediol | 212 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 199 | 52 |
| Mounjaro | Tirzepatide | 198 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 195 | 75 |
| Linzess | Linaclotide | 191 | 47 |
| Jardiance | Empagliflozin | 187 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 48 |
| Glimepiride | Glimepiride | 176 | 42 |
| Celecoxib | Celecoxib | 175 | 46 |
| Vascepa | Icosapent Ethyl | 161 | 45 |
| Azithromycin | Azithromycin | 158 | 94 |
| Famotidine | Famotidine | 157 | 43 |
| Januvia | Sitagliptin Phosphate | 157 | 28 |
| Furosemide | Furosemide | 147 | 34 |
| Lisinopril | Lisinopril | 134 | 29 |
| Meloxicam | Meloxicam | 131 | 56 |
| Sertraline Hcl | Sertraline Hcl | 128 | 32 |
| Gemtesa | Vibegron | 122 | 32 |
| Mirtazapine | Mirtazapine | 122 | 39 |
| Alendronate Sodium | Alendronate Sodium | 119 | 25 |
| Trulicity | Dulaglutide | 118 | 26 |
| Enalapril Maleate | Enalapril Maleate | 117 | 22 |
| Simvastatin | Simvastatin | 116 | 34 |
| Dicyclomine Hcl | Dicyclomine Hcl | 114 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 29 |
| Tramadol Hcl | Tramadol Hcl | 106 | 24 |
| Allopurinol | Allopurinol | 101 | 27 |
| Eliquis | Apixaban | 101 | 28 |
| Memantine Hcl | Memantine Hcl | 101 | 20 |
| Donepezil Hcl | Donepezil Hcl | 96 | 20 |
| Glipizide Er | Glipizide | 95 | 21 |
| Baclofen | Baclofen | 93 | 37 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 89 | 35 |
| Meclizine Hcl | Meclizine Hcl | 87 | 39 |
| Ezetimibe | Ezetimibe | 86 | 21 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 85 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 26 |
| Pregabalin | Pregabalin | 85 | 22 |
| Tradjenta | Linagliptin | 85 | 18 |
| Bumetanide | Bumetanide | 83 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 24 |
| Ibandronate Sodium | Ibandronate Sodium | 78 | 27 |
| Ammonium Lactate | Ammonium Lactate | 77 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 76 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 75 | 14 |
| Montelukast Sodium | Montelukast Sodium | 75 | 22 |
| Finasteride | Finasteride | 74 | 25 |
| Icosapent Ethyl | Icosapent Ethyl | 72 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 31 |
| Zenpep | Lipase/Protease/Amylase | 70 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 19 |
| Carvedilol | Carvedilol | 67 | 17 |
| Myrbetriq | Mirabegron | 67 | 17 |
| Ibuprofen | Ibuprofen | 62 | 33 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 62 | 22 |
| Alcohol Pads | Alcohol Antiseptic Pads | 59 | 16 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 59 | suppressed |
| Cyclosporine | Cyclosporine | 55 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 54 | 16 |
| Rybelsus | Semaglutide | 53 | suppressed |
| Sucralfate | Sucralfate | 52 | suppressed |
| Valsartan | Valsartan | 51 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | 19 |
| Creon | Lipase/Protease/Amylase | 50 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 49 | suppressed |
| Hydrocortisone | Hydrocortisone | 49 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 49 | 14 |
| Clonazepam | Clonazepam | 48 | 13 |
| Lidocaine | Lidocaine | 46 | 14 |
| Minoxidil | Minoxidil | 45 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 16 |
| Potassium Chloride | Potassium Chloride | 42 | suppressed |
| Glipizide | Glipizide | 41 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 39 | 13 |
| Colchicine | Colchicine | 39 | 12 |
| Ketoconazole | Ketoconazole | 39 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Ranolazine Er | Ranolazine | 39 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Kerendia | Finerenone | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Lactulose | Lactulose | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Proctozone-Hc | Hydrocortisone | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 24 |
| Prolia | Denosumab | 31 | 18 |
| Retacrit | Epoetin Alfa-Epbx | 31 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 13 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 14 |
| Rectiv | Nitroglycerin | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 16 |
| Mupirocin | Mupirocin | 27 | 11 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 24 | 16 |
| Loperamide | Loperamide Hcl | 24 | 12 |
| Metolazone | Metolazone | 24 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 24 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Repaglinide | Repaglinide | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Restasis | Cyclosporine | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | 17 |
| Levofloxacin | Levofloxacin | 21 | 20 |
| Metformin Er Gastric | Metformin Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Lubiprostone | Lubiprostone | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 14 |
| Ondansetron Odt | Ondansetron | 17 | 12 |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Jublia | Efinaconazole | 16 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 15 | suppressed |
| Alphagan P | Brimonidine Tartrate | 14 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Terconazole | Terconazole | 14 | suppressed |
| Alogliptin | Alogliptin Benzoate | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Prednisone | Prednisone | 13 | 12 |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Vyzulta | Latanoprostene Bunod | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $992.45 · 63 records | Novo Nordisk Inc | AIRSUPRA, CREON, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, KISUNLA, Kerendia, LINZESS, MOUNJARO, NUZYRA, Ohtuvayre, Ozempic, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Veozah, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error